Pharma Pulse: Eli Lilly’s Multi-Dose Breakthrough and Gilead’s $7.8 Billion Oncology Bet

Feb 24, 10:30 AM

Headliner
Share
Subscribe
In today’s Pharma Pulse, Eli Lilly launches the monthly Zepbound KwikPen to streamline obesity care, while Gilead Sciences acquires Arcellx in a massive expansion of its cell therapy portfolio.
Share
Subscribe
Next
Pharma Pulse: FDA’s Regulatory Revolution and Astellas’ $2 Billion Prostate Cancer Bet
Top episodes
Overcoming Supply Chain Challenges
by Pharmaceutical Commerce
Incorporating AI into Commercialization Plans
by Pharmaceutical Commerce
The Capabilities of a 3PL Provider
by Pharmaceutical Commerce